FilingSEC EDGAR8-K
Coya Therapeutics Completes Patient Enrollment for Phase 2/3 ALS Trial
· SEC accepted
StagePhase 2/3
Filing content
Coya Therapeutics completed enrollment of 120 patients for its Phase 2/3 ALSTARS trial of COYA 302, with topline data expected in early Q2 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…